Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo

This is an open-label, single-arm, multicenter, prospective, phase II clinical study to evaluate the efficacy and safety of TACE combined with Atezolizumab and Bevacizumab as neoadjuvant treatment in Hepatocellular Carcinoma.

Trial Details

NCT ID
NCT07239245
Phase
PHASE2
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • Atezolizumab
  • Bevacizumab
  • Transarterial chemoembolization (TACE)
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Zhengzhou, Henan, China|34.75778,113.64861
  • Shenyang, Liaoning, China|41.79222,123.43278
  • Taiyuan, Shanxi, China|37.86944,112.56028

Key Eligibility Criteria

  • Signed Informed Consent Form available
  • Patients ≥ 18 years and ≤75years of age at time of signing Informed Consent Form
  • Diagnosis of HCC confirmed by histology
  • Initially resectable with high-risk recurrence factors. High-risk features for resected patients include tumor size \>5 cm, tumor number \>3, vascu…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →